Crinetics Pharmaceuticals Inc
Company Profile
Business description
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Contact
6055 Lusk Boulevard
San DiegoCA92121
USAT: +1 858 450-6464
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
594
Stocks News & Analysis
stocks
Alphabet raises $80 billion for AI efforts
stocks
SpaceX: What investors need to know about its enormous upcoming IPO
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,017.20 | 3.10 | -0.03% |
| CAC 40 | 8,153.96 | 55.13 | -0.67% |
| DAX 40 | 24,818.76 | 305.41 | -1.22% |
| Dow JONES (US) | 50,999.30 | 308.49 | -0.60% |
| FTSE 100 | 10,349.23 | 24.28 | -0.23% |
| HKSE | 25,633.21 | 405.11 | -1.56% |
| NASDAQ | 26,910.60 | 183.30 | -0.68% |
| Nikkei 225 | 68,402.13 | 1,667.89 | 2.50% |
| NZX 50 Index | 13,115.08 | 55.63 | -0.42% |
| S&P 500 | 7,571.84 | 37.94 | -0.50% |
| S&P/ASX 200 | 8,785.70 | 5.90 | 0.07% |
| SSE Composite Index | 4,083.97 | 8.87 | 0.22% |